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Efficacy of Ubisol-Q10 Treatment in a Transgenic Mouse 
Model of Alzheimer’s Disease
ALZHEIMER'S DISEASE
WHAT IS ALZHEIMER’S DISEASE?
Most common neurodegenerative disorder worldwide, affecting 46.8 million individuals   
https://cdn.evbuc.com/eventlogos/40265082/old.jpg
• Most common form of 
dementia 
• Characterized by the 
deterioration of neuronal 
synapses and widespread 
neuronal death in the 
brain1
• This produces enlarged 
brain ventricles and cortical 
shrinkage
WHAT IS ALZHEIMER’S DISEASE?
http://www.synsys.eu/general-public
https://stanfordhealthcare.org/medical-conditions/brain-and-nerves/alzheimers-disease.html
• Two hallmarks of the disease: 
1. Amyloid-β Peptide (Aβ) Plaques 
2. Neurofibrillary Tangles containing 
Tau Protein2
• Tau proteins, found abundantly 
in the CNS, stabilize axonal 
microtubules
• Tangles are thought to be due to 
imbalance between Aβ 
production and clearance2
WHAT IS ALZHEIMER’S DISEASE?
https://www.alzheimer-forschung.de/alzheimer-krankheit/illustrationen_plaquesfibrillen.htm
http://healthland.time.com/2012/02/03/is-alzheimers-caused-by-contagious-proteins/
• Cholinergic neurons specifically 
targeted3
• Specific region may be the nucleus 
basalis of Meynert – shown  to 
deteriorate by more than 75%4
• Neuronal cell bodies in the basal 
forebrain3
• Innervate many areas of the 
cerebral cortex, thus cognitive 
functions such as memory are 
compromised3
WHICH NEURONS & BRAIN REGIONS ARE 
INVOLVED? 
https://psychiatricdrugs.com/neurology/acetylcholine/
https://neuroamer.wordpress.com/page/2/
AD SYMPTOMS
Memory loss
Language 
problems
Difficulty with simple tasks
Disorientation
Loss of 
reasoning 
capacity 
Loss of 
initiative
Behavioural changes 
Emotional changes 
Lost objects 
Difficulty with 
elaborate 
thoughts
http://www.doc-advice.com/alzheimers-disease/
CURRENT TREATMENTS
• No cure 
• Symptomatic relief only
• Drug treatments include:5
• Cholinesterase inhibitors –
ReminylER, Exelon, Aricept1
• NMDA receptor antagonists –
Ebixa (Memantine Hydrochloride)
• Non-pharmaceutical treatments:5
• Music therapy
• Pet therapy
• Aromatherapy & massage
• Natural health products
http://www.superama.com.mx/
http://www.lundbeck.com/pt/produtos/neurologia/ebixa
http://www.founduseful.com/natural-health-products-online-and-over-the-phone/
http://www.indexmundi.com/canada/age_structure.html
• Oxidative stress as a possible mechanism for 
neurodegeneration6
• What is oxidative stress? 
• Some of the O2 we breathe reacts to form 
free radicals  destabilize essential cell 
components 
• Damage known as oxidative stress
• Young, healthy  strong compensatory/ 
defense mechanisms to prevent oxidative 
damage
• Ageing weakens defenses such that ROS 
accumulate  apoptosis can be triggered7
PERHAPS OXIDATIVE STRESS? 
http://www.kappit.com/tag/hydrogen-jokes/
WHAT IS CoQ10?
• CoQ10, part of the ETC, sequesters electrons and stabilizes the mitochondria. 
This reduces the oxidative damage taking place. CoQ10 levels decline with age 9
https://www.pinterest.com/pin/488851734528172000/
ARE ANTIOXIDANTS THE ANSWER? 
• Antioxidants have been tested 
in the past
• Oil-soluble formulation of 
Coenzyme-Q10 was assessed 
– showed neuroprotection, but 
LOW bioavailability8
• Very high effective doses: 400-
1600 mg/kg/day8
• For 70kg human  112g/day8
http://www.drblayney.com/Medical/
WATER-SOLUBLE UBISOL-Q10
CoQ10 α-tocopherol
PEG
NANOMICELLULAR FORMULATION – UBISOL-Q10
COENZYME-Q10
Our NRC collaborators synthesized a water-soluble formulation of CoQ10, known 
as Ubisol-Q10 which is much more bioavailable
http://www.longevitylink.com/coenzyme-q10-supplement-facts-for-healthcare-professionals/
PREVIOUS WORK – PARKINSON’S DISEASE
Environmental Toxin PD Rat Model – therapeutic10
• Senescence:  in response to stressors and damage, cells can adopt a 
permanent state of cell-cycle arrest
PREVIOUS WORK – ALZHEIMER’S DISEASE12
• Autophagy: a cellular stress response in which there is sequestration 
and breakdown of harmful or dysfunctional cellular components
• Engulf damaged proteins/ organelles into autophagosome
• Autophagosome fuses with lysosome  autolysosome
• Degradation of cellular proteins
• RT2PCR Array analysis showing genes related to autophagy
PREVIOUS WORK – ALZHEIMER’S DISEASE13
SO WHAT NOW? 
Can the Ubisol-Q10 formulation provide
neuroprotection in an in vivo animal 
model?
http://www.shutterstock.com/similar-44436877/stock-photo-cartoon-of-a-man-who-is-stressed-out-and-develops-hives.html
TRANSGENIC MOUSE MODEL OF AD
• Transgenic mice, predisposed to develop early-onset AD, were 
obtained
• Mice had two mutant human genes inserted: 
• Human amyloid-precursor protein (APP)
• Human presenilin-1 (PS-1)
PS-1 (γ-secretase complex)  APP  Aβ
http://www.nature.com/nature/journal/v425/n6958/fig_tab/425565a_F1.html
Obtained 
transgenic 
mice, 
predisposed 
to early-
onset AD
Established 
control & 
experimental 
groups
Monitored 
mice for 
14 months
Obtained 
blood 
samples & 
sacrificed 
mice to 
extract 
brains
Performed 
biochemical 
analyses & 
immunohistoche
mistry 
EXPERIMENTAL DESIGN
Control – regular drinking water
Experimental – Ubisol-Q10 supplemented 
water 
• ELISA
• RT2PCR
http://ninjuni.cf/how/how-to-draw-a-cartoon-cat-and-mouse.html http://www.how-to-draw-funny-cartoons.com/cartoon-brain.html
http://www.pd4pic.com/test/ http://www.clker.com/clipart-6247.html
IMMUNOHISTOCHEMISTRY – DECREASED 
AMYLOID-Β PLAQUES IN BRAIN TISSUE   
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RT2PCR analyses still underway
FUTURE DIRECTIONS
• Understand if autophagy can be 
restored in the in vivo model 
through RT2PCR analysis
• Extend to other genetic models of 
AD  PS-2 , APP10
• Ultimately hope to develop 
Ubisol-Q10 as a treatment for 
those struggling with 
Alzheimer’s disease
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